Provance, Olivia K. http://orcid.org/0000-0003-1970-5791
Oria, Victor O. http://orcid.org/0000-0001-7187-7916
Tran, Thuy T. http://orcid.org/0000-0002-6244-7575
Caulfield, Jasmine I. http://orcid.org/0000-0002-0175-968X
Zito, Christopher R. http://orcid.org/0009-0006-6070-3287
Aguirre-Ducler, Adam
Schalper, Kurt A. http://orcid.org/0000-0001-5692-4833
Kluger, Harriet M. http://orcid.org/0000-0002-4932-9873
Jilaveanu, Lucia B. http://orcid.org/0000-0001-8900-5083
Funding for this research was provided by:
National Cancer Institute (R01CA204002, R01CA269286, K12CA215110, P50CA121974, T32 CA193200-5)
American Cancer Society (130157-RSG-16-216-01-TBG)
National Center for Advancing Translational Sciences (TL1TR001864)
H2020 Marie Skłodowska-Curie Actions (945322)
Article History
Received: 1 September 2023
Revised: 20 March 2024
Accepted: 21 March 2024
First Online: 18 April 2024
Declarations
:
: HMK holds institutional research grants from Merck, Bristol-Myers Squibb and Apexigen. HMK personal fees are associated with Iovance, Celldex, Merck, Bristol-Myers Squibb, Clinigen, Shionogi, Chemocentryx, Calithera, Signatero, Gigagen, GI Reviewers, Seranova, Pliant Therapeutics, and Esai. KAS is a consultant, advisor or speaker for Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, EMD Serono, Takeda, Torque/Repertoire Therapeutics, Moderna Inc., Tesaro/GSK, Agenus, Genmab, OnCusp, Parthenon Therapeutics, Abbvie, Sanofi, Janssen, Bristol-Myers Squibb, Roche, Regeneron, PeerView, Forefront collaborataive, Molecular Templates and Merck. KAS holds research funding from Tesaro/GSK, Takeda, Surface Oncology, Merck, Bristol-Myers Squibb, AstraZeneca, Ribon Therapeutics, Eli Lilly, Boehringer-Ingelheim, Roche and Akoya Biosciences. However, this research has been conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest with these studies.
: All animal studies were approved by Yale University Institutional Animal care and Use Committee (IACUC) (Study # 2020-20152). Melanoma tumor(s) were collected with the approval of the Yale University Human Investigations Committee (Institutional Review Board, Yale HIC# 0609001869).
: Not applicable.
: All authors consent to the publication of this study.